AN2 Therapeutics, Inc. said it plans to advance oral epetraborole into a Phase 2 proof-of-concept study in adults with phlebotomy-dependent polycythemia vera, and expects to initiate the trial in the third quarter of 2026, with periodic public data updates as early as the fourth quarter of 2026, subject to regulatory clearance and enrollment progress. The company cited results from multiple clinical trials in healthy volunteers and non-PV patients showing early, controlled, sustained, dose-dependent reductions in hematocrit at potentially clinically meaningful levels, including sustained effects over a six-month treatment period in clinical populations and durable hematocrit reduction in 9-month chronic non-human primate studies. It also reported no clinically relevant change in white blood cell counts and minimal change in platelet counts, and said epetraborole has been generally well tolerated at doses anticipated for PV.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260303819156) on March 03, 2026, and is solely responsible for the information contained therein.